We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · September 17, 2020

Hyperphosphatemia Secondary to Infigratinib Is Associated With Antitumor Efficacy in FGFR3-Altered Advanced/Metastatic Urothelial Carcinoma

European Urology


Additional Info

European Urology
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated With Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-Altered Advanced/Metastatic Urothelial Carcinoma
Eur Urol 2020 Aug 23;[EPub Ahead of Print], Y Lyou, P Grivas, JE Rosenberg, J Hoffman-Censits, DI Quinn, D P Petrylak, M Galsky, U Vaishampayan, U De Giorgi, S Gupta, H Burris, J Rearden, A Li, H Wang, M Reyes, S Moran, S Daneshmand, D Bajorin, SK Pal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading